Items 21 to 30 of 107 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $31.00 | 3 | |
Niflumic acid exhibits a selective inhibition of COX-2 through its unique ability to form hydrogen bonds with key amino acid residues in the enzyme's active site. This interaction alters the enzyme's conformation, reducing its catalytic efficiency. The compound's lipophilic nature enhances membrane permeability, facilitating its access to target sites. Additionally, its distinct electronic properties influence reaction kinetics, allowing for a nuanced modulation of inflammatory mediators. | ||||||
9-cis-Retinoic acid | 5300-03-8 | sc-205589 sc-205589B sc-205589C sc-205589D sc-205589A | 1 mg 25 mg 250 mg 500 mg 5 mg | $70.00 $416.00 $3060.00 $5610.00 $145.00 | 10 | |
9-cis-Retinoic acid acts as a selective modulator of COX-2 by engaging in specific hydrophobic interactions with the enzyme's active site, promoting a conformational shift that diminishes its enzymatic activity. Its unique stereochemistry allows for enhanced binding affinity, while its ability to participate in π-π stacking interactions with aromatic residues further stabilizes the enzyme-inhibitor complex. This compound's dynamic behavior in lipid environments also influences its interaction kinetics, providing a sophisticated mechanism for regulating inflammatory pathways. | ||||||
(S)-Ibuprofen | 51146-56-6 | sc-200612 sc-200612A | 1 g 5 g | $47.00 $140.00 | 4 | |
(S)-Ibuprofen selectively inhibits COX-2 through its unique chiral structure, which facilitates precise interactions with the enzyme's active site. The compound's hydrophobic regions enhance binding affinity, while its ability to form hydrogen bonds with key amino acid residues contributes to a stable enzyme-inhibitor complex. Additionally, (S)-Ibuprofen's conformational flexibility allows it to adapt within the active site, influencing reaction kinetics and modulating inflammatory responses effectively. | ||||||
Sulindac sulfide | 32004-67-4 | sc-200118 sc-200118A | 5 mg 25 mg | $73.00 $226.00 | 2 | |
Sulindac sulfide exhibits selective inhibition of COX-2 by engaging in specific hydrophobic interactions with the enzyme's active site. Its unique structural features allow for the formation of stable π-π stacking interactions with aromatic residues, enhancing binding affinity. The compound's electron-withdrawing groups facilitate charge distribution, influencing reaction kinetics and promoting a favorable conformational arrangement that stabilizes the enzyme-inhibitor complex. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide acts as a selective COX-2 inhibitor through its unique ability to form hydrogen bonds with key amino acid residues in the enzyme's active site. Its distinct molecular structure allows for effective steric hindrance, which disrupts the enzyme's catalytic activity. Additionally, Leflunomide's hydrophilic regions enhance solubility, promoting efficient interaction dynamics, while its conformational flexibility aids in optimizing binding affinity and specificity. | ||||||
Deracoxib | 169590-41-4 | sc-482703 | 25 mg | $150.00 | ||
Deracoxib is another COX-2 inhibitor used in veterinary medicine. It reduces inflammation and pain by selectively inhibiting COX-2 and reducing prostaglandins. | ||||||
Tenidap | 120210-48-2 | sc-204334 sc-204334A | 10 mg 50 mg | $160.00 $580.00 | 1 | |
Tenidap functions as a selective COX-2 inhibitor by engaging in specific hydrophobic interactions with the enzyme's active site, which stabilizes its binding. Its unique structural features facilitate the formation of π-π stacking interactions with aromatic residues, enhancing selectivity. The compound's kinetic profile reveals a rapid association and slower dissociation, indicating a strong affinity for COX-2. Furthermore, its conformational adaptability allows for optimal alignment within the enzyme's binding pocket. | ||||||
(S)-(+)-Flurbiprofen | 51543-39-6 | sc-205503 sc-205503A sc-205503B sc-205503C | 10 mg 50 mg 1 g 1.5 g | $32.00 $140.00 $1025.00 $1841.00 | 1 | |
(S)-(+)-Flurbiprofen acts as a selective COX-2 inhibitor through its unique stereochemistry, which enhances its interaction with the enzyme's active site. The compound exhibits a distinctive ability to form hydrogen bonds with key amino acid residues, promoting a stable enzyme-inhibitor complex. Its kinetic behavior is characterized by a moderate rate of association and a prolonged residence time, suggesting effective inhibition. Additionally, the compound's lipophilicity aids in its preferential binding to the COX-2 isoform over COX-1. | ||||||
Meclofenamate sodium | 6385-02-0 | sc-200532 sc-200532A | 1 g 5 g | $51.00 $77.00 | 2 | |
Meclofenamate sodium functions as a selective COX-2 inhibitor, distinguished by its unique structural conformation that facilitates specific interactions with the enzyme's active site. This compound exhibits a notable propensity for π-π stacking interactions with aromatic residues, enhancing binding affinity. Its reaction kinetics reveal a rapid onset of inhibition, coupled with a reversible binding mechanism, allowing for dynamic modulation of COX-2 activity. The compound's hydrophilic nature contributes to its solubility, influencing its distribution in biological systems. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $31.00 $84.00 $147.00 | 3 | |
Sulindac acts as a selective COX-2 inhibitor, characterized by its unique dual-ring structure that allows for specific hydrogen bonding with the enzyme's active site. This compound demonstrates a distinct ability to stabilize transition states during enzymatic reactions, influencing its inhibition kinetics. Its lipophilic properties enhance membrane permeability, facilitating effective interaction with cellular targets. Additionally, Sulindac's metabolic pathways involve conversion to active sulfide forms, further modulating its biological effects. |